Profile of Dennis Dawson ElliottContact: [email protected] My desire to serve Indiana University began while an undergraduate student in the tumultuous 1960’s when protests in Dunn Meadow over the Vietnam War and the diverse political environment demanded a commitment to burrow deep into the reasons and opinion that were to impact my future. The campus environment was stimulating and responsibilities at the Indiana Daily Student and other news organizations created an atmosphere that encouraged personal involvement on many levels.After graduation I began a 22-year career with Bristol-Myers in Evansville, Indiana that placed me on the front lines of premier medical research, working both domestically and internationally. At the time I chose to leave the company 1989 to become executive vice president of a multi-division communications company in New York, I was the director of advertising for the company’s five pharmaceutical and nutritional divisions, a position that honed my administrative and financial management skills, and human capital succession planning.It was during this period I developed an understanding of philanthropy development through the Bristol-Myers foundation. Concurrently I served on the board and was president of the IU Alumni Club of Southern Indiana for many years and worked to establish an annual scholarship for a deserving high school senior planning to attend IU.Prior to returning to the Bloomington campus in 2007 to join the faculty of the School of Journalism I led and supervised the accreditation of two continuing medical education companies. These organizations provided the opportunity to pursue my continuing research orientation while developing educational programs for physicians in the fields of oncology, central nervous system disorders and cardiovascular medicine. During this period I also served as vice president and senior strategist for a communications organization in New York.Being an officer in these companies did not detract from my ongoing involvement with IU. I returned to campus for career day presentations and discussion panels for students and as a member of the Journalism Alumni Board. In 2006 I was appointed the School of Journalism representative on the executive committee for the “Matching the Promise” $1.1 billion funding campaign.Until my retirement from the Bloomington faculty in 2014 my connectivity to student learning and their concerns was continually evolving. I listened, I counseled, and I was rewarded by observing their development, and today former students frequently keep me informed of their career successes. I served on a number of campus boards and committees including the Dean of Students Advisory Committee, the IU Cinema Board of Advisors, as a Faculty Fellow for the Office of Service Learning, and as a Hutton Honors Resident Fellow. I was also the faculty advisor for a student professional organization, advisor for a campus wide honor society and was a sponsor of student athletes as they began their academic studies.As a research committed university IU’s reputation is strong. My orientation to research as the precursor to informed action continues to this day as I continue research on the use of technology as a communication tool for the education and management of HIV/AIDS in Sub-Saharan Africa.I support the multi-discipline research collaboration approach that uses the strongest attributes of these disciplines to work toward robust and innovative outcomes. I support research as the catalyst for documented insight across initiatives that will reflect positively on the university.I look to the university to lead attitude change on all of our campuses and be a leader nationwide in addressing the issue of sexual assault. Process and policy must be preceded by student education and student commitment to change the assault paradigm.As a candidate for the Board of Trustees my awareness of the Board’s purpose, priorities and accomplishments has been developed through informed observation, discussions with alumni and fellow faculty members and reviewing Board meeting agendas and administrative actions. My desire to serve on the Board of Trustees is a reflection of my full-circle commitment to the university. My knowledge and perspective from my time as a faculty member will help guide meaningful personal contributions in the form of discussion and insightful proposals while fulfilling committee assignments and collaboration on new initiatives important to the university pursuit of excellence.I look forward to active involvement in a fashion that will effectively apply my experience from management positions in corporate America and from time on the Bloomington campus as a faculty member. My career has been rewarding, with profound recognition of the solid foundation from my IU education. I believe my skills and insights developed through the years will complement the competencies of fellow Board members as we work collaboratively for immediate benefits as well as the long-term advancement of the university. I appreciate the support of alumni to place me in a position to represent them and I welcome contact through email at [email protected] LinkEmail
2020 tokyo olympicsequestrianfouaad mirza First Published: November 23, 2019, 8:06 AM IST Get the best of News18 delivered to your inbox – subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what’s happening in the world around you – in real time. New Delhi: Double Asian Games medallist equestrian Fouaad Mirza secured an Olympic quota after finishing as the top-ranked rider in his group in the qualifiers, ending a wait spanning nearly two decades.The 27-year-old was the highest ranked rider in Group G for the South East Asia, Oceania in the individual eventing category after the end of the Europe stage earlier this month. However, the official confirmation will be announced by the International Equestrian Federation (FEI) on February 20.Imtiaz Anees (2000 Sydney) and Late Wing Commander IJ Lamba (1996 Atlanta) are the only Indians to have represented the country at the Olympics.Mirza, who was honoured with the Arjuna Award in August, finished with a total of 64 points from six qualifying events.He scored 34 points on his first horse Fernhill Facetime and 30 with his second horse Touchingwood.”I had an idea that I was in the reckoning for the quota but had to wait for China and Thailand to qualify as teams. Both of them qualified last week in Italy. If these two countries had not qualified as teams they would have taken up the individual slots and I wouldn’t have got the Olympic berth,” Mirza told PTI from Germany.The riders had to compete at 4 star level tournaments for Olympic qualifications. Based on an elaborate ranking system, a rider-horse duo collects points by taking part in tournaments throughout the year.To gain points the rider has to finish in the top 25 percent of the number of competitors participating in the tournament. The higher the athlete is ranked in the competition the more points he gets.”I am elated but there’s still enough work to be done. It’s one tick out of the many boxes. Now we have to prepare the best we can and enter the competition in top form,” Mirza said.Earlier this year, Mirza’s top horse Seigneur Medicott had suffered an injury, denting the Asian Games silver medallists chances of qualification. But the horses have worked out well for Mirza.”I miss my main horse, but the two new ones are doing well. They have worked out for me. They aren’t as good as Medicott but I am pleased to see how the season has progressed with them. They have worked well to come this far and to reach this level,” Mirza said.Mirza shot to fame when he became the first Indian since 1982 to win an Asian Games individual medal in equestrian besides guiding the country to a second-place finish in the team competition in Jakarta last year.”I am very grateful to the Embassy Group and Mr Jitu Virwani for giving me the opportunity to qualify for the Games. They have funded the entire project and Mr Virwani and the Embassy Group were behind the success at the Asian Games,” he said.
Source:https://medicine.wustl.edu/news/scientists-identify-weak-point-in-deadly-eye-melanoma/ Reviewed by Alina Shrourou, B.Sc. (Editor)Sep 6 2018A natural plant compound exploits a newly identified Achilles’ heel in a cancer of the eye, uveal melanoma. In human cancer cells growing in the lab, the compound shuts down the overactive signaling that drives uveal melanoma cell growth, according to researchers at Washington University School of Medicine in St. Louis.The study is published Sept. 4 in the journal Science Signaling.Uveal, or ocular, melanoma arises from the layer of pigmented cells of the eye that includes the iris. Fatal in about half of the patients who develop it, the cancer represents about 3 to 5 percent of all melanoma cases. Unlike skin melanoma, uveal melanoma is not strongly linked to exposure to ultraviolet light, although, the researchers note, individuals with blue eyes and fair skin are at highest risk of developing the disease.”In about half of patients, this tumor metastasizes to other organs and grows aggressively,” said senior author Kendall J. Blumer, PhD, a professor of cell biology and physiology. “Skin melanoma now has a number of relatively new targeted therapies, including immune therapies, that prolong survival, even after tumors have spread. Unfortunately, these treatments don’t seem to do much against uveal melanoma. So there is a need for new therapeutics in this specific type of tumor.”Scientists have been studying the signaling molecules that are overactive in uveal melanoma for a decade but have had little clinical success in shutting them down. The overactive protein commonly found in this specific type of melanoma is called G alpha q, and it is part of a class of molecules called G proteins. When such proteins develop genetic errors that permanently switch them on, cancer can result.In its active state, G alpha q is bound to another molecule that keeps it turned on and the signaling cascade flowing all the time. In the search for therapies in uveal melanoma, scientists have tried many different strategies to shut down individual pieces of the cascade activated by G alpha q. Thus far, no approach has succeeded in helping patients with the disease.Related StoriesUAMS-developed noninvasive device detects melanoma in earliest stages’Eye-in-a-dish’ model helps scientists to uncover ‘surprising’ AMD gene variantStudy shows high incidence of herpes zoster ophthalmicus among older adultsThe new study suggests a solution that is surprising in its simplicity. Rather than turning off parts of the cascade activated by G alpha q, the scientists showed they could simply wait for G alpha q to release the molecule that keeps it active. This random split happens at a low rate, according to the researchers, but if a drug is present that can trap G alpha q in its inactive state, the researchers thought that the entire cancer-causing signaling cascade would gradually shut down, one protein at a time.The researchers found that a natural compound called FR900359 (FR) — present in a member of the primrose family of plants — does just that.”This plant compound binds tightly to inactive G alpha q, trapping it in its deactivated state,” Blumer said. “When the cancer-causing form of G alpha q just happens to switch off on its own, FR traps it there.”Added first author Michael D. Onken, PhD, an assistant professor of biochemistry and molecular biophysics: “In our study, we showed that the cancer-causing form of G alpha q doesn’t have to be turned off by force. It just turns itself off every now and then on its own. But it then can be locked down with FR, and that’s enough to shut down tumor cell growth.”Indeed, the researchers showed that FR not only kills human uveal melanoma cells growing in the lab, it also appeared to revert a subset of those cells back to a state resembling normal pigmented cells of the eye.G proteins are common throughout the body, so finding ways to deactivate them also could be potentially relevant for other disorders, including cholera and Sturge-Weber Syndrome, a neurological disorder that often causes seizures and muscle weakness. Evidence also links such proteins to common disorders affecting large numbers of people, including asthma and high blood pressure.Blumer, Onken and their colleagues now are planning to test whether the FR compound can treat uveal melanoma in mouse models of the disease.